m6A-modification of cyclin D1 and c-myc IRESs in glioblastoma controls ITAF activity and resistance to mTOR inhibition
Cancer Letters · 2023
DOI: 10.1016/j.canlet.2023.216178 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2023. Verfasst von Angelica Benavides-Serrato und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of California, Los Angeles, CA, USA; Department of Research & Development, Greater Los Angeles Veterans Affairs He…. Hauptthemen laut MEDLINE: Cyclin D1, Glioblastoma. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: BLRD VA, NCI NIH HHS.
Abstract (Originalsprache)
A major mechanism conferring resistance to mTOR inhibitors is activation of a salvage pathway stimulating internal ribosome entry site (IRES)-mediated mRNA translation, driving the synthesis of proteins promoting resistance of glioblastoma (GBM). Previously, we found this pathway is stimulated by the requisite IRES-trans-acting factor (ITAF) hnRNP A1, which itself is subject to phosphorylation and methylation events regulating cyclin D1 and c-myc IRES activity. Here we describe the requirement for m6A-modification of IRES RNAs for efficient translation and resistance to mTOR inhibition. DRACH-motifs within these IRES RNAs upon m6A modification resulted in enhanced IRES activity via increased hnRNP A1-binding following mTOR inhibitor exposure. Inhibitor exposure stimulated the expression of m6A-methylosome components resulting in increased activity in GBM. Silencing of METTL3-14 complexes reduced IRES activity upon inhibitor exposure and sensitized resistant GBM lines. YTHDF3 associates with m6A-modified cyclin D1 or c-myc IRESs, regulating IRES activity, and mTOR inhibitor sensitivity in vitro and in xenograft experiments. YTHDF3 interacted directly with hnRNP A1 and together stimulated hnRNP A1-dependent nucleic acid strand annealing activity. These data demonstrate that m6A-methylation of IRES RNAs regulate GBM responses to this class of inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of California, Los Angeles, CA, USA; Department of Research & Development, Greater Los Angeles Veterans Affairs Healthcare System, Los Angeles, CA, USA.
- Department of Research & Development, Greater Los Angeles Veterans Affairs Healthcare System, Los Angeles, CA, USA.
- Neurology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA, USA; Department of Research & Development, Greater Los Angeles Veterans Affairs Healthcare System, Los Angeles, CA, USA.
- Department of Medicine, University of California, Los Angeles, CA, USA; Jonnson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA; Molecular Biology Institute, University of California, Los Ang…
Förderung
- BLRD VA
- NCI NIH HHS
Zitieren
APA
Benavides-Serrato, A., Saunders, J. T., Kumar, S., Holmes, B., Benavides, K. E., Bashir, M. T., Nishimura, R. N., & Gera, J. (2023). m6A-modification of cyclin D1 and c-myc IRESs in glioblastoma controls ITAF activity and resistance to mTOR inhibition. Cancer Letters. https://doi.org/10.1016/j.canlet.2023.216178
Vancouver
Benavides-Serrato A, Saunders JT, Kumar S, Holmes B, Benavides KE, Bashir MT, et al. m6A-modification of cyclin D1 and c-myc IRESs in glioblastoma controls ITAF activity and resistance to mTOR inhibition. Cancer Letters. 2023. doi:10.1016/j.canlet.2023.216178
BibTeX
@article{BenavidesSerrato2023,
author = {Benavides-Serrato, Angelica and Saunders, Jacquelyn T and Kumar, Sunil and Holmes, Brent and Benavides, Kennedy E and Bashir, Muhammad T and Nishimura, Robert N and Gera, Joseph},
title = {m6A-modification of cyclin D1 and c-myc IRESs in glioblastoma controls ITAF activity and resistance to mTOR inhibition},
journal = {Cancer Letters},
year = {2023},
doi = {10.1016/j.canlet.2023.216178}
}
EUVIMED